Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
DENTSPLY SIRONA Inc. director Brian P. McKeon filed an initial Form 3, which is a required statement of beneficial ownership for insiders. This filing establishes his reporting status as a director of the company but does not report any specific buy or sell transactions.
DENTSPLY SIRONA Inc. director James D. Forbes filed an initial ownership report on Form 3. This filing establishes his status as an insider, including his role as a director of the company. The Form 3 does not report any share purchases or sales, and serves as a baseline disclosure of his insider position.
Dentsply Sirona Inc. filed its annual report describing a large global business focused on professional dental products, digital equipment, clear aligners, implants and continence care, selling into about 140 countries through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare.
The company highlights long-term industry tailwinds such as aging populations, aesthetic dentistry, digital workflows and emerging-market demand, and notes that roughly two-thirds of dental products are sold through distributors, with Henry Schein and Patterson each representing around or above 10% of sales or receivables in some years.
Management plans to increase research and development to about 5% of net sales beginning in 2026, emphasizing cloud-based DS Core, CAD/CAM systems and AI-powered tools. The report describes significant cybersecurity, data-privacy and AI-related risks, as well as extensive global regulatory requirements for medical devices, anti-bribery, and data protection.
Dentsply Sirona outlines recent and ongoing restructuring programs, including a 2026 plan expected to generate about $120 million in annualized cost savings after non-recurring charges of approximately $55–$65 million, and discusses risks from ERP implementation, tariffs, geopolitical tensions, and a German tax investigation tied to past intercompany loans.
DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported a small share disposition tied to equity compensation. On the transaction date, 1,194.48 shares of common stock were withheld at a price of $13.14 per share to cover taxes on vested restricted stock units and related dividend equivalent units. After this tax-withholding disposition, Scavilla directly owned 16,750.066 shares of DENTSPLY SIRONA common stock.
Dentsply Sirona reported Q4 2025 net sales of $961 million, up 6.2%, but a net loss of $146 million or ($0.74) per share, mainly from $144 million of goodwill and intangible impairments. Full-year 2025 net sales were $3.68 billion, down 3.0%, with a net loss of $598 million or ($3.00) per share.
On a non-GAAP basis, Q4 adjusted EPS was $0.27 and full-year adjusted EPS was $1.60. The company generated Q4 free cash flow of $60 million and full-year free cash flow of $104 million, ending 2025 with $326 million in cash and cash equivalents.
The Board approved a restructuring plan expected to create about $120 million in annualized cost savings, with $55–$65 million in non-recurring charges largely in 2026–2027. Dentsply Sirona also eliminated its quarterly dividend to redirect capital toward debt reduction and share repurchases. For 2026, it targets net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50.
DENTSPLY SIRONA Inc. increased the size of its Board of Directors from 11 to 13 members and appointed James D. Forbes and Brian P. McKeon as new directors, effective February 27, 2026. They will serve until the director elections at the 2026 annual meeting of stockholders.
Forbes, a veteran healthcare investment banker with experience advising on more than $200 billion in financings and over $100 billion in M&A, will join the Compensation & Human Capital Committee. McKeon, a long-tenured public company CFO and director, will join the Audit and Finance Committee and the Science and Technology Committee.
The company highlights that their strategic and financial expertise is intended to support execution of its Return-to-Growth action plan and long-term value creation efforts. Long-serving director Willie A. Deese plans to retire from the Board and will not stand for re-election, and his decision is stated not to result from any disagreement with the company.
DENTSPLY SIRONA Inc. increased the size of its Board of Directors from 11 to 13 members and appointed James D. Forbes and Brian P. McKeon as new directors, effective February 27, 2026. They will serve until the director elections at the 2026 annual meeting of stockholders.
Forbes, a veteran healthcare investment banker with experience advising on more than $200 billion in financings and over $100 billion in M&A, will join the Compensation & Human Capital Committee. McKeon, a long-tenured public company CFO and director, will join the Audit and Finance Committee and the Science and Technology Committee.
The company highlights that their strategic and financial expertise is intended to support execution of its Return-to-Growth action plan and long-term value creation efforts. Long-serving director Willie A. Deese plans to retire from the Board and will not stand for re-election, and his decision is stated not to result from any disagreement with the company.
Lazard Asset Management LLC reported beneficial ownership of 8,733,942 shares of DENTSPLY SIRONA Inc, representing 4.4% of the equity class as of 12/31/2025. Lazard has sole power to vote and dispose of all these shares.
The firm states the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of DENTSPLY SIRONA, nor in connection with any control-related transaction.
AQR Capital Management Holdings, LLC and its wholly owned subsidiary AQR Capital Management, LLC report beneficial ownership of DENTSPLY SIRONA Inc. common stock. They disclose beneficially owning 4,898,136 shares, representing 2.45% of the outstanding common stock.
The firms report shared voting and dispositive power over all of these shares and no sole voting or dispositive power. They certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of DENTSPLY SIRONA.
DENTSPLY SIRONA Inc. director Donald Zurbay reported a stock-based award from the company. On 01/26/2026, he was granted 6,871 shares of common stock at a price of $0, reflecting an equity grant rather than a purchase.
According to the footnote, the award consists entirely of Restricted Stock Units that vest in full one year from the grant date, after which the restrictions lapse. Following this grant, Zurbay beneficially owns 6,871 shares directly, aligning his interests more closely with shareholders through additional equity compensation.
DENTSPLY SIRONA Inc. director Donald J. Zurbay filed an initial ownership report on Form 3 stating that he does not beneficially own any company securities. The filing confirms his status as a director and notes, in the remarks section, that no securities are beneficially owned.